105 related articles for article (PubMed ID: 7118326)
21. Clinical pharmacology of torasemide, a new loop diuretic.
Brater DC; Leinfelder J; Anderson SA
Clin Pharmacol Ther; 1987 Aug; 42(2):187-92. PubMed ID: 3608350
[TBL] [Abstract][Full Text] [Related]
22. Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide.
Kim YC; Lee MG; Ko SH; Kim SH
J Pharm Pharmacol; 2003 Nov; 55(11):1515-22. PubMed ID: 14713362
[TBL] [Abstract][Full Text] [Related]
23. Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of torasemide in rabbits.
Kim YC; Lee MG; Ko SH; Kim SH
Biopharm Drug Dispos; 2004 Jul; 25(5):211-8. PubMed ID: 15248190
[TBL] [Abstract][Full Text] [Related]
24. The loop diuretic torasemide in chronic renal failure. Pharmacokinetics and pharmacodynamics.
Knauf H; Spahn H; Mutschler E
Drugs; 1991; 41 Suppl 3():23-34. PubMed ID: 1712713
[TBL] [Abstract][Full Text] [Related]
25. Chemistry and pharmacological properties of the pyridine-3-sulfonylurea derivative torasemide.
Delarge J
Arzneimittelforschung; 1988 Jan; 38(1A):144-50. PubMed ID: 3370058
[TBL] [Abstract][Full Text] [Related]
26. The pharmacokinetics and diuretic effects of piretanide in chronic renal insufficiency.
Berg KJ; Walstad RA; Bergh K
Br J Clin Pharmacol; 1983 Mar; 15(3):347-53. PubMed ID: 6342640
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic and pharmacodynamic properties of orally administered torasemide in healthy cats.
Roche-Catholy M; Paepe D; Devreese M; Broeckx BJG; Woehrlé F; Schneider M; de Salazar Alcala AG; Hellemans A; Smets P
J Vet Intern Med; 2022 Sep; 36(5):1782-1791. PubMed ID: 35906901
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of torasemide and its metabolites in end-stage renal disease.
Krämer BK; Schwab A; Braun N; Strutz F; Müller GA; Risler T
Eur J Clin Pharmacol; 1994; 47(2):157-9. PubMed ID: 7859803
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological properties of 3-n-butylamino-4-phenoxy-5-sulfamylbenzoic acid (Bumetanide), a new potent diuretic.
Ostergaard EH; Magnussen MP; Nielsen CK; Eilertsen E; Frey HH
Arzneimittelforschung; 1972 Jan; 22(1):66-72. PubMed ID: 5067001
[No Abstract] [Full Text] [Related]
30. Renal responses and pharmacokinetics of piretanide in humans: effect of route of administration, state of hydration and probenecid pretreatment.
Noormohamed FH; McNabb WR; Dixey JJ; Lant AF
J Pharmacol Exp Ther; 1990 Sep; 254(3):992-9. PubMed ID: 2395126
[TBL] [Abstract][Full Text] [Related]
31. [Pharmacokinetic study of a new diuretic: torasemide in man (author's transl)].
Clerckx-Braun F; Lesne M
J Pharm Belg; 1980; 35(3):223-4. PubMed ID: 7400925
[No Abstract] [Full Text] [Related]
32. Pharmacokinetics of a new diuretic, torasemide, in man.
Lesne M; Clerckx-Braun F; Duhoux F; van Ypersele C
Arch Int Pharmacodyn Ther; 1981 Feb; 249(2):322-5. PubMed ID: 7224731
[No Abstract] [Full Text] [Related]
33. Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin.
Kim YC; Oh EY; Kim SH; Lee MG
Biopharm Drug Dispos; 2005 Nov; 26(8):371-8. PubMed ID: 16094676
[TBL] [Abstract][Full Text] [Related]
34. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
[TBL] [Abstract][Full Text] [Related]
35. Renal action of a novel uricosuric diuretic, S-8666. I. Clearance and tubular microinjection studies in rats.
Shimuizu T; Nakamura M; Imai M
J Pharmacol Exp Ther; 1988 May; 245(2):644-50. PubMed ID: 3367310
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic-pharmacodynamic relationship of piretanide in healthy and uremic subjects. Determinants of the diuretic effect of a loop diuretic.
Sjöström P; Beermann B; Odlind B
Scand J Urol Nephrol; 1987; 21(1):55-64. PubMed ID: 3589526
[TBL] [Abstract][Full Text] [Related]
37. Effects of cardiac failure on the pharmacokinetics of the diuretic tizolemide.
Beermann B; Edelstam C
Eur Heart J; 1984 Apr; 5(4):338-42. PubMed ID: 6734643
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and bioavailability of piretanide in healthy volunteers following intramuscular administration.
Trenk D; Wagner F; Jähnchen E; Spahn H; Mutschler E
Arzneimittelforschung; 1987 Dec; 37(12):1382-5. PubMed ID: 3449067
[TBL] [Abstract][Full Text] [Related]
39. A sulphonylthiourea (BM 20) related to torasemide: a new loop diuretic with relative potassium-sparing properties.
Masereel B; Schynts M; Krzesinski JM; Pirotte B; Rorive G; Delarge J
J Pharm Pharmacol; 1993 Aug; 45(8):720-4. PubMed ID: 7901370
[TBL] [Abstract][Full Text] [Related]
40. Clopamide: plasma concentrations and diuretic effect in humans.
McNeil JJ; Conway EL; Drummer OH; Howes LG; Christophidis N; Louis WJ
Clin Pharmacol Ther; 1987 Sep; 42(3):299-304. PubMed ID: 3621784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
